Alliance for Clinical Trials in Oncology
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Alliance for Clinical Trials in Oncology sits in the top decile of US sponsors by registered trial count (#80 of 15,742 sponsors by registered trial count).
Alliance for Clinical Trials in Oncology: 446 sponsored US clinical trials, 29 recruiting.
Alliance for Clinical Trials in Oncology sponsors 446 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 346 completed. 142 of these trials are in Phase 3-4 (later-stage) and 235 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 19 trials.
Top-decile sponsor footprint
Alliance for Clinical Trials in Oncology ranks in the top decile of sponsors by registered trial count (#80 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
346 of 377 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
446 total, page 7 of 9
Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer
NCT00028574
Radiosurgery With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
NCT00030628
Genetic Study of Familial Factors in Patients With Colon Cancer
NCT00055848
Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
NCT00033748
Vinorelbine in Treating Older Women With Stage IV Breast Cancer
NCT00022152
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
NCT00028925
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00028600
Screening Tests in Detecting Colorectal Cancer
NCT00025025
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00027573
Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer
NCT00023686
Irinotecan in Treating Aging Patients With Solid Tumors
NCT00026195
Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer
NCT00024102
Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer
NCT00026130
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer
NCT00026403
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
NCT00033696
Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer
NCT00006010
Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT00022646
Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00005850
Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer
NCT00026117
Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
NCT00017186
Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer
NCT00023751
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
NCT00020943
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
NCT00016913
Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
NCT00009893
ICI 182780 in Treating Women With Metastatic Breast Cancer
NCT00012025
Vinorelbine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00008333
Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer
NCT00016952
Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
NCT00010218
Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00006265
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
NCT00006012
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
NCT00006349
Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas
NCT00006467
Ceramide Cream in Treating Women With Cutaneous Breast Cancer
NCT00008320
Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas
NCT00012220
LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer
NCT00006007
Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer And Lung Dysfunction
NCT00009789
Green Tea Extract in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00005828
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
NCT00006747
Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer
NCT00005963
Capecitabine in Treating Patients With Malignant Mesothelioma
NCT00004183
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
NCT00005601
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
NCT00006348
Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
NCT00006483
Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer
NCT00899509
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
NCT00006359
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
NCT00005610
Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate
NCT00006214
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT00006029
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
NCT00006125
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer
NCT00005972
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 26 |
| Phase 2 | 209 |
| Phase 3 | 142 |
What is open in the Alliance for Clinical Trials in Oncology pipeline
29 recruiting of 446 indexed (7% open); 346 completed (78%).
Phase mix: 142 late (III/IV) vs 235 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alliance for Clinical Trials in Oncology: open-pipeline peers nationwide
Peers matched on 446 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Alliance for Clinical Trials in Oncology sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 446 trials (± recruiting share)
- Medical College of Wisconsin · 447 trials · 21% recruiting
- University of Virginia · 449 trials · 22% recruiting
- Children's Hospital of Philadelphia · 431 trials · 18% recruiting
- Novo Nordisk A/S · 431 trials · 8% recruiting
Sponsors near 7% open enrollment (± trial volume)
- National Institutes of Health Clinical Center (CC) · 7% recruiting · 338 trials
- Insmed Incorporated · 6% recruiting · 31 trials
- NICHD Neonatal Research Network · 7% recruiting · 61 trials
- Hennepin Healthcare Research Institute · 6% recruiting · 63 trials
Related
What to do with this Alliance for Clinical Trials in Oncology page
446 registered trials is a research-attention snapshot, not an endorsement of Alliance for Clinical Trials in Oncology or any single study.
- 29 of Alliance for Clinical Trials in Oncology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Alliance for Clinical Trials in Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Alliance for Clinical Trials in Oncology pipeline card: 446 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.